Retrospective Case Series of Aripiprazole Augmentation in Pervasive Developmental Disorders
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Due to co-morbidities and treatment resistant nature of pervasive developmental disorder (PDD), diverse combinations of regimens have been tried. This retrospective study aimed to explore adjunctive use of aripiprazole in children with PDD. Changes in illness severity were measured by Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Improvement (CGI-I) in 14 aripiprazole-treated patients with PDD. Improvement of illness severity was observed after aripiprazole add-on (5.8±0.8 to 4.9±1.0, Z=-2.75, p=0.001). Mean dosage was 7.7 mg/day [standard deviation (SD) 3.3, range 5-15]. A higher mean dosage was observed in group with improvement in symptoms (t=-2.33, df =12, p=0.004). The target symptoms most effectively improved after using aripiprazole were positive psychotic symptoms (mean CGI-I: 2.0±1.4, 3 responders/4 patients, 75% response) followed by aggressive behavior (2.5±1.7, 3/4, 75%), self-injurious behavior (2.0±1.0, 2/3, 67%), stereotypic behavior (2.7±1.2, 2/3, 67%), tic (2.8±1.0, 2/4, 50%), irritability (3.5±2.1, 1/2, 50%), obsessive behavior (2.5±2.1, 1/3, 33%), hyperactivity (3.4±1.6, 3/7, 43%) and mood fluctuation (3, 0/1, no response). Five patients (35%) discontinued aripiprazole due to treatment-emergent adverse effects (akathisia, insomnia, withdrawal). The results of this study suggest that aripiprazole augmentation may be used safely in maladaptive behaviors of some populations of PDD. However, future studies are required to con-firm these preliminary findings.
Abstract
Due to co-morbidities and treatment resistant nature of pervasive developmental disorder (PDD), diverse combinations of regimens have been tried. This retrospective study aimed to explore adjunctive use of aripiprazole in children with PDD. Changes in illness severity were measured by Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Improvement (CGI-I) in 14 aripiprazole-treated patients with PDD. Improvement of illness severity was observed after aripiprazole add-on (5.8±0.8 to 4.9±1.0, Z=-2.75, p=0.001). Mean dosage was 7.7 mg/day [standard deviation (SD) 3.3, range 5-15]. A higher mean dosage was observed in group with improvement in symptoms (t=-2.33, df =12, p=0.004). The target symptoms most effectively improved after using aripiprazole were positive psychotic symptoms (mean CGI-I: 2.0±1.4, 3 responders/4 patients, 75% response) followed by aggressive behavior (2.5±1.7, 3/4, 75%), self-injurious behavior (2.0±1.0, 2/3, 67%), stereotypic behavior (2.7±1.2, 2/3, 67%), tic (2.8±1.0, 2/4, 50%), irritability (3.5±2.1, 1/2, 50%), obsessive behavior (2.5±2.1, 1/3, 33%), hyperactivity (3.4±1.6, 3/7, 43%) and mood fluctuation (3, 0/1, no response). Five patients (35%) discontinued aripiprazole due to treatment-emergent adverse effects (akathisia, insomnia, withdrawal). The results of this study suggest that aripiprazole augmentation may be used safely in maladaptive behaviors of some populations of PDD. However, future studies are required to con-firm these preliminary findings.
참고문헌 (10)
- National Institutes of Health, "‘Autism fact sheet’ NINDS" (2006), National Institutes of Health
- butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity, "J Pharmacol Exp Ther", 1995, 329~336
- Findling RL, "A multi-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia", Am J Psychiatry, 165, pp.1432~1441 (2008)
- Stigler KA, "Aripiprazole for maladaptive behavior in pervasive developmental disorders", J Child Adolesc Psychopharmacol, 14, pp.455~463 (2004)
- Andersen SE, "The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients", Basic Clin Pharmacol Toxicol, 103, pp.75~81 (2008)
- Stigler KA, "Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 14-week, prospective, open-label study", J Child Adolesc Psychopharmacol, 19, pp.265~274 (2009)
- Masi G, "Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study", CNS Drugs, 23, pp.511~521 (2009)
- Rugino TA, "Aripiprazole in children and adolescents: clinical experience", J Child Neurol, 20, pp.603~610 (2005)
- Valicenti-McDermott MR, "Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities", J Child Adolesc Psychopharmacol, 16, pp.549~560 (2006)
- Woods SW, "Chlorpromazine equvalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)